Results 71 to 80 of about 29,034 (242)

One delayed diagnosis of paragonimiasis case and literature review

Respirology Case Reports, 2021
Human paragonimiasis has been appearing all over the world due to increased human migration, international travel, and worldwide food trading. However, delayed and missed diagnosis rates are also increasing due to atypical clinical manifestations and the
Luxia Kong, Lijuan Hua, Qian Liu, Chen Bao, Jiannan Hu, Shuyun Xu   +5 more
doaj   +1 more source

Phenotypic and genotypic monitoring of Schistosoma mansoni in Tanzanian schoolchildren five years into a preventative chemotherapy national control programme [PDF]

, 2017
We conducted combined in vitro PZQ efficacy testing with population genetic analyses of S. mansoni collected from children from two schools in 2010, five years after the introduction of a National Control Programme.
A Fenwick, A Koukounari, AE Lelo, AJ Norton, AW Cheever, CD Criscione, Charlotte M. Gower, CM Gower, CM Gower, DG Colley, Florian Gehre, J Goudet, J Liu, J Wang, J Zwang, Joanne P. Webster, JP Webster, JP Webster, JW Rudge, LL Cavalli-Sforza, LM Barbosa, M Aemero, ML Steinauer, Nicholas J. Lwambo, OR Jones, PH Lamberton, PH Lamberton, PJ Hotez, Poppy H. L. Lamberton, RM Anderson, S William, Sara R. Marques, T Crellen, T de Meeus, T Huyse, WHO, YS Liang, ZN Kamvar   +37 more
core   +3 more sources

Enhancing schistosomiasis drug discovery approaches with optimized proteasome substrates

Protein Science, Volume 34, Issue 6, June 2025.
Abstract Schistosomiasis, a neglected tropical disease infecting over 200 million people globally, has limited therapeutic options. The 20S proteasome is a validated drug target for many parasitic infections, including those caused by Plasmodium and Leishmania, and we have previously demonstrated antischistosomal activity with inhibitors targeting ...
Elany B. Silva, Zhenze Jiang, Chenxi Liu, Pavla Fajtová, Thaiz R. Teixeira, Giovana de Castro Fiorini Maia, Lawrence J. Liu, Nelly El‐Sakkary, Danielle E. Skinner, Ali Syed, Steven C Wang, Conor R. Caffrey, Anthony J. O'Donoghue   +12 more
wiley   +1 more source

Does the presence of praziquantel-related adverse events affect the health community's perception toward the mass chemopreventive program in the highest prevalence area of Schistosomiasis in Indonesia? Study in Dodolo village, Napu Valley, Central Sulawesi

Gaceta Sanitaria, 2021
Objective: This study was to determine the relationship between a praziquantel-related adverse event with the health community perception to chemopreventive of Schistosomiasis in Dodolo village, Napu Valley, Central Sulawesi.
Ayu Sekarani Damana Putri, T. Vera Diana, Rahma Daris, Fitri Afriana, Serli Hatul Hidayat   +4 more
doaj  

Efficacy and safety of praziquantel in preschool-aged and school-aged children infected with Schistosoma mansoni: a randomised controlled, parallel-group, dose-ranging, phase 2 trial

The Lancet Global Health, 2017
Background: Praziquantel has been the drug of choice for schistosomiasis control for more than 40 years, yet surprisingly, the optimal dose for children younger than 4 years is not known.
Jean T Coulibaly, PhD, Gordana Panic, PhD, Kigbafori D Silué, PhD, Jana Kovač, MSc, Jan Hattendorf, PhD, Prof Jennifer Keiser, PhD   +5 more
doaj   +1 more source

Effect of praziquantel treatment of Schistosoma mansoni during pregnancy on immune responses to schistosome antigens among the offspring: results of a randomised, placebo-controlled trial. [PDF]

, 2011
BACKGROUND: Offspring of women with schistosomiasis may exhibit immune responsiveness to schistosomes due to in utero sensitisation or trans-placental transfer of antibodies.
Cose, Stephen, Dunne, David W, Elliott, Alison M, Jones, Frances M, Kihembo, Macklyn, Mawa, Patrice A, Tweyongyere, Robert, Vennervald, Birgitte J, Webb, Emily L   +8 more
core   +5 more sources

Estimation of changes in the force of infection for intestinal and urogenital schistosomiasis in countries with Schistosomiasis Control Initiative-assisted programmes [PDF]

, 2015
The last decade has seen an expansion of national schistosomiasis control programmes in Africa based on large-scale preventative chemotherapy. In many areas this has resulted in considerable reductions in infection and morbidity levels in treated ...
A Garba, AD Barbour, AD Barbour, AJ Fulford, AJ Fulford, Alan Fenwick, Amadou Garba, AP Plaisier, AP Plaisier, ARC Harris, AW Cheever, B Bolker, B Payet, BL Webster, BL Webster, BL Webster, BR Kirkwood, CH King, CH King, D Engels, D Gurarie, DL Smith, E Michael, E Miguel, EK N'Goran, Elisa Bosqué-Oliva, Fiona M. Fleming, G Webbe, GA Macdonald, GE Box, GF Medley, H Laamrani, H Tanaka, Hairston NG, HC Turner, HC Turner, HP Duerr, I Nåsell, I Nåsell, J Utzinger, J Utzinger, James Mwansa, JH Ouma, Joanne P. Webster, JP Webster, JW Rudge, JW Rudge, L Van Etten, LA Tchuem-Tchuenté, LA Tchuem-Tchuenté, Lynsey Blair, M Booth, M Parker, M Tanner, M-G Basáñez, M-G Basáñez, Maria-Gloria Basáñez, ME Woolhouse, Michael D. French, ML Steinauer, Moussa Sacko, MS Chan, MS Chan, MS Chan, N Katz, Narcis B. Kabatereine, NB Kabatereine, NG Hairston, RM Anderson, RM Anderson, RM Anderson, RM Anderson, RM May, Seydou Toure, SJ de Vlas, SM Blower, Team" RDC, Thomas S. Churcher, Ursuline Nyandindi, WHO   +79 more
core   +3 more sources

First Molecular Characterization of the Zoonotic Parasite Balantioides coli in Brachyteles hypoxanthus Wied, 1820 (Primate: Atelidae) in Brazil

Journal of Medical Primatology, Volume 54, Issue 3, June 2025.
ABSTRACT Fecal samples from seven individuals kept in semi‐captivity in Minas Gerais were subjected to microscopic and molecular parasitological techniques. Balantioides coli was identified in all samples with a predominance of an atypical variant. This is the first molecular characterization of B. coli in Brachyteles hypoxanthus in Brazil.
Laís Verdan Dib, Mikaelly Frasson Testa, Fernanda Marocolo Quintão, Fernanda Pedreira Tabacow, Fabiano Rodrigues de Melo, Marcello Silva Nery, Camila Souza Carvalho Class, Alynne da Silva Barbosa   +7 more
wiley   +1 more source

Two-year longitudinal survey reveals high genetic diversity of Schistosoma mansoni with adult worms surviving praziquantel treatment at the start of mass drug administration in Uganda

Parasites & Vectors, 2019
Background A key component of schistosomiasis control is mass drug administration with praziquantel. While control interventions have been successful in several endemic regions, mass drug administration has been less effective in others. Here we focus on
Christina L. Faust, Marco Crotti, Arinaitwe Moses, David Oguttu, Aidah Wamboko, Moses Adriko, Elizabeth K. Adekanle, Narcis Kabatereine, Edridah M. Tukahebwa, Alice J. Norton, Charlotte M. Gower, Joanne P. Webster, Poppy H. L. Lamberton   +12 more
doaj   +1 more source

A new global strategy for the elimination of schistosomiasis

International Journal of Infectious Diseases, 2017
Mass drug administration utilising a single oral dose of 40 mg/kg of praziquantel (PZQ) has been endorsed and advocated by the World Health Organisation (WHO) for the global control and elimination of schistosomiasis.
Allen G.P. Ross, M.D., Ph.D., Thao N. Chau, M.P.H., Marianette T. Inobaya, M.Sc., Remigio M. Olveda, M.D., Yuesheng Li, M.D, Ph.D, Donald A. Harn, Ph.D.   +5 more
doaj   +1 more source